Synapse - Jonathan Rosenberg

Search Within

Jonathan Eric Rosenberg

Results (520)

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Meeting Abstract

Rosenberg, J. E.; Bajorin, D. F.; Smith, A.; D'Cruz, C.; Lanasa, M.
Annals of Oncology (2018)

Fulltext@MSK | Save

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Meeting Abstract

Rudin, C. M.; Pandha, H. S.; Gupta, S.; Zibelman, M. R.; Akerley, W.; Day, D.; Hill, A. G.; Sanborn, R. E.; O'Day, S. J.; Clay, T. D.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

Meeting Abstract

Petrylak, D. P.; Rosenberg, J.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E.; Melhem-Bertrandt, A.; Powles, T.
Annals of Oncology (2018)

Fulltext@MSK | Save

Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)

Meeting Abstract

Galsky, M. D.; Banchereau, R.; Kadel, E. E. 3rd; Ramirez-Montagut, T.; Mariathasan, S.; Thåström, A.; Rosenberg, J.; Powles, T.; van der Heijden, M. S.; Necchi, A.
Annals of Oncology (2018)

Fulltext@MSK | Save

Robot-assisted versus open radical cystectomy in patients receiving perioperative chemotherapy for muscle-invasive bladder cancer: The oncologist's perspective from a multicentre study

Journal Article

Necchi, A.; Pond, G. R.; Smaldone, M. C.; Pal, S. K.; Chan, K.; Wong, Y. N.; Viterbo, R.; Sonpavde, G.; Harshman, L. C.; Crabb, S.; more...
European Urology Focus (2018)

Fulltext@MSK | Save

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

Journal Article

Leiserson, M. D. M.; Syrgkanis, V.; Gilson, A.; Dudik, M.; Gillett, S.; Chayes, J.; Borgs, C.; Bajorin, D. F.; Rosenberg, J. E.; Funt, S.; more...
PLoS ONE (2018)

Fulltext@MSK | Save

Novel therapies in urothelial carcinoma: A biomarker-driven approach

Journal Article

Iyer, G.; Rosenberg, J. E.
Annals of Oncology (2018)

Fulltext@MSK | Save

Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC)

Meeting Abstract

Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Dalbagni, G.; Bochner, B. H.; Funt, S.; Iyer, G.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study

Meeting Abstract

Sharma, P.; Callahan, M. K.; Bono, P.; Kim, J. W.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; De Braud, F. G.; Morse, M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study

Meeting Abstract

Petrylak, D. P.; Smith, D. C.; Flaig, T. W.; Zhang, J.; Sridhar, S. S.; Ruether, J. D.; Plimack, E. R.; Merchan, J. R.; Quinn, D. I.; Kilari, D.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save